As far as immunotherapy is concerned, it has been recently observed that the E2/ERα ratio was able to predict the response to pembrolizumab in patients with NSCLC, also suggesting the use of aromatase inhibitors as possible sex-specific immunoadjuvants in this type of tumor [169]. This evidence concerns the gene ESR1 and neoplasm.